Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down – Time to Sell?

Shares of Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $22.2775, but opened at $21.11. Hikma Pharmaceuticals shares last traded at $21.10, with a volume of 22,673 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on HKMPF shares. Barclays upgraded shares of Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 8th. Citigroup reiterated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Moderate Buy”.

Get Hikma Pharmaceuticals alerts:

Check Out Our Latest Stock Analysis on HKMPF

Hikma Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $21.79 and its 200-day moving average price is $19.77. The company has a quick ratio of 1.06, a current ratio of 1.82 and a debt-to-equity ratio of 0.57.

Hikma Pharmaceuticals Company Profile

(Get Free Report)

Hikma Pharmaceuticals plc is a multinational pharmaceutical company that develops, manufactures and markets a broad portfolio of medicines. Its products include generic and specialty pharmaceuticals, injectable medicines, and branded treatments across a range of therapeutic areas.

The company operates through three principal businesses: Injectables, which supplies hospital and clinical medicines; Generics, which offers off-patent prescription products, primarily in the United States; and Branded, which markets medicines under established brand names across the Middle East and North Africa.

Featured Stories

• Five stocks we like better than Hikma Pharmaceuticals
• Lockheed’s Stock Hasn’t Priced In Its Own Backlog—Boeing’s Might Already Have
• Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?
• Old Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom
• 3 Tech Stocks Positioned for More Upside if the Sector’s Breakout Holds

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.